BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

JLL/Delta Dutch Newco B.V. Announces Offering Of $500 Million Senior Notes Due 2022


1/16/2014 6:53:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JLL/Delta Dutch Newco B.V. Announces Offering of $500 Million Senior Notes due 2022

NEW YORK, Jan. 16, 2014 /PRNewswire/ -- JLL/Delta Dutch Newco B.V. (the "Company") announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior Notes due 2022 (the "Notes"). The Company intends to use the net proceeds from the offering of the Notes as part of its financing for its previously-announced transactions pursuant to which the Company has agreed to acquire the outstanding equity securities of Patheon Inc. (PTI.TO) and the pharmaceutical products business of Koninklijke DSM N.V. (the "Acquisitions"). It is expected that the proceeds of the offering will be deposited in escrow subject to the completion of the Acquisitions and satisfaction other customary conditions. Upon consummation of the Acquisitions, the Notes will be guaranteed, jointly and severally, by the Company's existing and future subsidiaries that are guarantors under the Company's senior secured credit facilities that will be entered into in connection with the financing of the Acquisitions.

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), in the United States only to investors who are "qualified institutional buyers," as that term is defined in Rule 144A under the Securities Act, or outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of the Notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES